Oliver is the founder of 20one Consulting Ltd, a consulting company based in Cambridge, England, focusing on the emerging science of slowing and reversing the fundamental aging processes in humans.
20one Consulting applies the following to achieve its mission:
His evidence-based enterprises also cover
I received my medical degree from King's College London, England (KCL) and discovered during training a passion for solving systems-level problems in health care and aging .
Today, I work on accelerating the adoption of clinical evidence, across diagnostics, prognostics and interventions into my Longevity Level 1, 2, 3 medical specialty, enabling patients and clinicians globally to use the most evidence-based tests and therapies in a safe, effective and rationale way.
I also consult companies developing Longevity Level 3 therapies to de-risk their chance of assets in their pipeline failing, as well as to enhance the upside of positive trial results.
Oliver earned his M.B.B.S. from King's College London, England (equivalent to the US M.D.) and also earnt a BSc in Regenerative Medicine, Aging & Medical Device Innovation Technology, with First Class Honours.
Oliver has received the following awards:
Disclosures & disclaimer
Why did I not proceed with NHS consultancy training after graduating?
Whilst I received interviews for the Academic Foundation Program at Oxford and Severn Foundation Schools, in 2018-19, as well as an F1 job offer, I decided to not go ahead with F1 training or further, or to to activate my UK registration or license.
This is because since the beginning of medical school I have been planning to manage systems at scale, and individual clinical practise, whilst providing further clinical gestalt, comes at the huge opportunity cost of not being able to develop knowledge, skills and network outside of standard clinical medicine that are needed to transition society to a post-aging society. Whilst these knoweldge and skills overlap with Old-age/Geriatric medicine, General Practice, Pharmacetical Medicine, Lifestyle Medicine and Oncology somewhat - on my assessment there is ultimately no medical speciality training route in the NHS for me that would provide me the highest probability of helping society cure age-related diseases and fundamental aging pathology as soon as possible.
As a result, I chose to undertake the following strategy:
Supporting clinicians to practise Longevity Level 1, 2, 3 evidence-based medicine
- Writing gold-standard clinical practice evidence-based guidelines for Longevity Level 1, 2, 3 medicine (AGREE-II, PRISMA etc.) (e.g. see www.longevity.school/methodology for an example of how content is created)
- Developing scalable ways to train licensed clinicians in gold standard evidence-based Longevity Level 1, 2, 3 medicine pan-jurisdictionally
- Developing supporting clinical and clinical research software to enable clinicians to practise Longevity Level 1, 2, 3 medicine more easily (given current electronic health record software is inadequate for this)
- Managing ethical approval, off label prescribing, unlicensed prescribing and clinical research projects in patients to develop high quality evidence of safety and efficacy (ultimately to generate high quality evidence of multi-decade reversal of high-quality aging biomarkers in all organs in clients)
- Involving clinicians in the research process to develop new Longevity Level 3 therapies
Supporting patients to make truly informed Longevity related decisions and implement them
- Creating gold-standard international patient decision aid (IPDAS) compliant patient decision aids on key decision longevity decision topics patients face
- Creating software and resources for patients to manage their longevity
- To help patients avoid scams and excessive risk
- Involving patients in the research process to develop new Longevity Level 3 therapies
Supporting the development of Longevity Level 3 therapies
- Supporting the development of new Longevity Level 3 tests and therapies through financing, investor awareness, regulatory advice, patent strategy, preclinical & phase 1 - 4 trial design etc.
- Integrating these new Longevity Level 3 therapies into clinical practice rapidly, through developing clinical guidelines for these therapies and integrateing these into the Longevity Level 1, 2, 3 medicine clinical guidelines and practitioner/clinic network
Whilst I may provide "informational/educational advice" rather than medical advice to people - i.e. these are the studies I found from a systematic review of the literature on PubMed for your condition and these are the key points or references I suggest you should discuss with your licensed doctor based on my experience, caveated with a lengthy disclaimer, I am not able to provide medical advice, having no license or registration to practise in any jurisdiction. See our medical disclaimer.